Skip to main content

Health condition · Clinically reviewed

Bile duct cancer, from Klatskin tumours to TOPAZ-1 and targeted therapy.

A rare but rising cancer where anatomy, molecular profiling and a specialist HPB team all shape the plan. Modern immunotherapy and targeted options are changing outcomes.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, BSG, ESMO and peer-reviewed hepato-pancreato-biliary sources.

  • 03

    Current for 2026

    Reflects TOPAZ-1 and KEYNOTE-966 immunotherapy standards plus FGFR2 and IDH1 targeted options.

Key facts

Bile duct cancer at a glance.

A quick orientation to the anatomy, risk factors, prognosis and the current UK treatment standards.

  • What it is

    Cholangiocarcinoma, a cancer of the bile duct lining, classified by where along the biliary tree it arises.

  • Three anatomical types

    Intrahepatic (10 to 20%), perihilar or Klatskin (50 to 60%) and distal extrahepatic (20 to 30%).

  • Biggest risk factor

    Primary sclerosing cholangitis lifts lifetime risk by roughly 400 times, alongside liver flukes, hepatolithiasis and viral hepatitis.

  • Classic presentation

    Painless obstructive jaundice with pruritus, pale stools, dark urine, weight loss and fatigue.

  • Prognosis

    Five-year survival is under 20% overall, and complete surgical resection remains the only realistic route to cure.

  • 2026 systemic standard

    Gemcitabine, cisplatin and durvalumab (TOPAZ-1) is first-line for unresectable or metastatic disease, with FGFR2 and IDH1 targeted options for eligible tumours.

Why this guide matters

Anatomy, molecular profile, and a specialist team.

Cholangiocarcinoma sits at the crossroads of hepatology, oncology and complex surgery. Three principles run through every decision on this page.

  • Location defines the operation

    Intrahepatic, perihilar and distal tumours need very different surgical procedures. The plan starts with high-quality MRCP and CT.

  • Molecular profiling changes options

    FGFR2 fusions, IDH1 mutations, HER2 and NTRK now open targeted therapy pathways. Profiling should be requested early.

  • Immunotherapy is now first-line

    TOPAZ-1 and KEYNOTE-966 established gemcitabine, cisplatin and immunotherapy as the new systemic standard for advanced disease.

How the diagnosis is made

From first jaundice to a defined MDT plan.

The steps a hepatologist and HPB oncologist will normally follow in a specialist UK centre.

  1. 01

    Suspecting

    Liver function tests

    An obstructive pattern with raised ALP, GGT and conjugated bilirubin is the usual first signal.

  2. 02

    Suspecting

    Tumour markers

    CA 19-9 and CEA support the picture but are not specific and are commonly elevated in any cholestasis.

  3. 03

    Suspecting

    Ultrasound first-line

    A quick way to demonstrate ductal dilation, a mass or gallbladder involvement before more detailed imaging.

  4. 04

    Characterising

    MRI and MRCP

    The gold standard for characterising the biliary tree, defining tumour extent and staging perihilar disease.

  5. 05

    Characterising

    Staging CT and PET-CT

    CT of chest, abdomen and pelvis for metastatic staging, with PET-CT used selectively for equivocal nodes or lesions.

  6. 06

    Characterising

    ERCP with brushings and biopsy

    Direct sampling of a stricture, often combined with intraductal ultrasound (IDUS) or SpyGlass cholangioscopy for visualised biopsy.

  7. 07

    Personalising

    Molecular profiling

    FGFR2 fusions, IDH1 mutations, HER2, MSI or MMR status, BRAF, KRAS and NTRK increasingly steer targeted therapy.

Typical timeline: specialist HPB centres aim to reach a treatment decision within two to four weeks of referral.

Symptoms

What bile duct cancer looks like.

Painless jaundice with pruritus and dark urine is the classic presentation. Intrahepatic disease often shows up later with a mass, weight loss and vague pain.

  • Painless obstructive jaundice

    Yellowing of skin and sclera without pain is the hallmark, especially with distal or perihilar tumours.

  • Pruritus

    Intense itch from bile salt accumulation, often the most distressing early symptom.

  • Pale stools and dark urine

    A classic pair pointing to biliary obstruction rather than a hepatocellular process.

  • Weight loss and fatigue

    Constitutional symptoms are common and often prompt the first GP visit.

  • Right upper quadrant discomfort

    A dull ache rather than colicky pain, sometimes with a palpable gallbladder (Courvoisier sign) in distal disease.

  • Cholangitis

    Fever, rigors and jaundice (Charcot triad) can complicate obstruction and needs urgent decompression.

  • Intrahepatic mass presentation

    Intrahepatic tumours often present later with a liver mass, weight loss and vague upper abdominal pain rather than jaundice.

  • Red flag - PSC with new jaundice

    Any patient with primary sclerosing cholangitis and a new stricture or rising CA 19-9 needs urgent hepatobiliary assessment.

Treatment

How bile duct cancer is treated in the UK.

Surgery when possible, adjuvant capecitabine after resection, and modern immunotherapy or targeted therapy for advanced disease.

  • Surgical resection

    The only curative option. Intrahepatic disease needs hepatectomy, perihilar needs extended hepatectomy with caudate lobe and Roux-en-Y hepaticojejunostomy, and distal disease needs a Whipple pancreaticoduodenectomy.

  • Liver transplant

    Reserved for highly selected early perihilar cholangiocarcinoma within protocols such as the Mayo neoadjuvant regimen.

  • Adjuvant capecitabine

    Six months of oral capecitabine after resection is the UK standard following the BILCAP trial.

  • Gem-cis-durvalumab (TOPAZ-1)

    Gemcitabine plus cisplatin with the immunotherapy durvalumab is the first-line regimen for unresectable or metastatic disease, with pembrolizumab (KEYNOTE-966) as an alternative.

  • FOLFOX second-line

    The ABC-06 trial established FOLFOX as the second-line chemotherapy standard after platinum-based failure.

  • Targeted therapy

    Pemigatinib, infigratinib and futibatinib for FGFR2 fusions, ivosidenib for IDH1 mutations, larotrectinib or entrectinib for NTRK fusions, and trastuzumab-based options for HER2.

  • Biliary drainage and stenting

    Endoscopic or percutaneous stenting (usually self-expanding metallic stents) relieves jaundice, prepares patients for surgery and palliates symptoms.

  • Locoregional therapies

    Transarterial chemoembolisation (TACE), yttrium-90 radioembolisation, external beam radiotherapy, photodynamic therapy and intraductal radiofrequency ablation (Habib probe) for selected patients.

What this guide is based on

The sources behind every claim on this page.

NICE, BSG and ESMO guidance alongside the practice-changing trials that shape current UK hepatobiliary oncology.

Key references

Guidelines, landmark trials and the UK charity.

A quiet reminder

This guide is for information, not medical advice.

Your hepatologist, HPB surgeon and oncologist know your imaging, molecular profile and history and can tell you which parts apply to you.

  • NICE. Cholangiocarcinoma: diagnosis and management guidance and quality standards.

  • British Society of Gastroenterology (BSG). Guidelines on the diagnosis and management of cholangiocarcinoma.

  • ESMO Clinical Practice Guidelines. Biliary tract cancer.

  • Oh D-Y et al. TOPAZ-1: durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer, NEJM Evidence 2022.

  • Kelley RK et al. KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin in biliary tract cancer, Lancet 2023.

  • AMMF - The Cholangiocarcinoma Charity. UK patient information and support resources.

Red flags

When to escalate urgently.

Cholangiocarcinoma pathways carry several time-critical complications. Any of these deserve same-day contact with the specialist team.

  • Cholangitis

    Fever, rigors and jaundice need urgent admission, blood cultures, IV antibiotics and biliary decompression, usually by ERCP or PTC.

  • Rapidly rising bilirubin

    A steep climb in bilirubin points to complete obstruction and warrants urgent imaging and drainage planning.

  • New jaundice on a PSC background

    Any patient with primary sclerosing cholangitis and new jaundice, weight loss or a rising CA 19-9 needs same-week hepatobiliary review.

  • Weight loss and anorexia

    Unintentional weight loss with abdominal symptoms in anyone over 40 should trigger a two-week wait upper GI referral.

  • Ascites or hepatomegaly

    New ascites or a hard, enlarged liver in this context suggests advanced or metastatic disease.

  • GI bleeding

    Haemobilia or upper GI bleeding after biliary intervention needs urgent interventional radiology or endoscopy.

  • Post-stent fever

    Fever after biliary stenting can mean stent occlusion, cholangitis or an abscess and needs urgent review.

  • Uncontrolled pruritus

    Severe itch that disrupts sleep despite treatment can be managed with cholestyramine, rifampicin, sertraline or naltrexone under specialist advice.

  • New confusion

    Encephalopathy in advanced disease needs urgent hepatology assessment and reversal of precipitants.

Living with it

A serious diagnosis, handled by the right team.

Four things make the biggest day-to-day difference: the right centre, active symptom control, careful nutrition and reliable support.

A quiet reminder

Symptom control is treatment, not an afterthought.

Effective drainage of jaundice, control of pruritus and pancreatic enzyme support after a Whipple often shape quality of life more than any single infusion.

  1. 01 Team

    A specialist HPB centre matters

    Care in a hepato-pancreato-biliary MDT with hepatology, oncology, interventional radiology and specialist nurses gives the best chance of a coordinated plan.

  2. 02 Symptoms

    Pruritus is treatable

    Cholestyramine, rifampicin, sertraline or naltrexone can transform quality of life. Do not accept unrelieved itch as unavoidable.

  3. 03 Nutrition

    Protect weight and muscle

    Early dietitian input, pancreatic enzyme replacement after a Whipple and small frequent meals help maintain strength through treatment.

  4. 04 Support

    AMMF and specialist nurses

    AMMF is the UK cholangiocarcinoma charity and a valuable source of information, peer support and clinical trial signposting.

Frequently asked

Everything we get asked about bile duct cancer.

Quick answers on risk factors, staging, surgery, TOPAZ-1 and jaundice management.

  • What is bile duct cancer?

    Bile duct cancer, or cholangiocarcinoma, is a cancer of the cells lining the bile ducts. It is classified by location as intrahepatic (within the liver), perihilar or Klatskin (at the hepatic duct confluence) or distal extrahepatic (in the common bile duct near the pancreas).

  • What are the main risk factors?

    Primary sclerosing cholangitis (PSC) is the strongest risk factor and can raise lifetime risk around 400 times. Others include chronic hepatolithiasis, hepatitis B and C, cirrhosis, liver flukes (Opisthorchis and Clonorchis in Southeast Asia), Caroli disease, choledochal cysts, historical thorotrast exposure, obesity, type 2 diabetes, smoking and alcohol.

  • How is it diagnosed?

    Diagnosis usually starts with obstructive liver blood tests, ultrasound and CA 19-9. MRI with MRCP is the gold standard for characterisation and staging. ERCP with brush cytology, biopsy, intraductal ultrasound or SpyGlass cholangioscopy gives tissue and direct visualisation. CT chest, abdomen and pelvis and selective PET-CT complete staging, and molecular profiling now guides treatment.

  • Can bile duct cancer be cured?

    Complete surgical resection is the only route to cure. The operation depends on location. Intrahepatic disease needs a hepatectomy, perihilar disease needs an extended hepatectomy with caudate lobe and Roux-en-Y hepaticojejunostomy, and distal disease needs a Whipple pancreaticoduodenectomy. A small number of highly selected early perihilar patients are considered for liver transplant within protocols. Even after resection, adjuvant capecitabine is standard for six months.

  • What is the standard treatment if surgery is not possible?

    For unresectable or metastatic disease the current first-line standard is gemcitabine and cisplatin combined with the immunotherapy durvalumab, based on the TOPAZ-1 trial. Pembrolizumab is an alternative per KEYNOTE-966. FOLFOX is the standard second-line option after ABC-06. Targeted drugs are used where molecular profiling shows FGFR2 fusions (pemigatinib, infigratinib, futibatinib), IDH1 mutations (ivosidenib), NTRK fusions or HER2 amplification.

  • How is jaundice managed?

    Biliary drainage relieves jaundice, pruritus and cholangitis and can optimise patients before surgery or palliate symptoms. Endoscopic or percutaneous stenting with self-expanding metallic stents (SEMS) is the usual approach. Pruritus itself is treated with cholestyramine, rifampicin, sertraline or naltrexone. Care is coordinated in a hepato-pancreato-biliary MDT with palliative and hepatology input.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.